Sign in
ImmunologybioRxiv
Preprint

A human monoclonal antibody bivalently binding two different epitopes in streptococcal M protein protects against infection

W. Bahnan, L. Happonen, H. Khakzad, V. Kumra Ahnlide, T. de Neergaard, S. Wrighton, O. Andre, E. Bratanis, D. Tang, T. Hellmark, L. Bjorck, O. Shannon, L. Malmstrom, J. Malmstrom, P. Nordenfelt

Abstract

Group A streptococci have evolved multiple strategies to evade human antibodies, making it challenging to create effective vaccines or antibody treatments. Here, we have generated antibodies derived from the memory B cells of an individual who had successfully cleared a group A streptococcal infection. The antibodies bind with high affinity in the central region of the surface-bound M protein. Such antibodies are typically non-opsonic. However, one antibody could effectively promote vital immune functions, including phagocytosis and in vivo protection. Remarkably, this antibody primarily interacts through a bivalent dual-Fab cis mode, where the Fabs bind to two distinct epitopes in the M protein. The dual-Fab cis binding phenomenon is conserved across different groups of M types. In contrast, other antibodies binding with normal single-Fab mode to the same region can not bypass the M proteins virulent effects. A broadly binding, protective monoclonal antibody could be a candidate for anti-streptococcal therapy. Our findings highlight the concept of dual-Fab cis binding as a means to access conserved, and normally non-opsonic regions, for protective antibody targeting.

PDFDOI

02 /Specification & Classification

Click any tag to browse matching papers

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISGingerich '22Wrighton '22Izadi '23Khakzad '21Ahnlide '20McCormick '26
69% semantic matchImmunology
A. D. Gingerich, F. Royer, A. L. McCormick+3 more·bioRxiv·Apr 20, 2022